Company intelligence / Profile preview

Chung Mei Biopharma

Ownership: Private
Development stage: Other

Overview

Chung Mei Biopharma focuses on botanic new drug R&D with its lead asset DCB-BO1301 targeting advanced melanoma. The investigational new drug has demonstrated efficacy in animal models and received US FDA IND clearance. The company also produces a wide range of OTC pharmaceuticals and health foods with cGMP/PIC/S GMP certifications. It collaborates closely with leading Taiwanese research institutions to advance novel therapies into clinical development while maintaining a strong commercial presence in Asia’s OTC market[5][6][7].

Therapeutic areas: OtherOncologyDermatology
Modalities: Botanical drugs (botanic new drug development)health foods/supplementsoral and solid pharmaceutical preparations
Industry: Biotech

Drug pipeline

2 assets

DCB-BO1301

1 more asset in the full pipeline.

Request access →

Partnerships

Academia SinicaDevelopment Center for Biotechnology (DCB)Pharmascience Canada

Beyond the preview

Go deeper on Chung Mei Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chung Mei Biopharma.

Explore the full profile